Paul Roepman
Overview
Explore the profile of Paul Roepman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
4814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verkerk K, van der Wel T, Zeverijn L, Geurts B, Spiekman I, de Wit G, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5323-5332.
PMID: 39352721
Purpose: To provide patients with MET-mutated advanced non-small cell lung cancer (METmut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in this setting, and find potential...
2.
Zeverijn L, Geurts B, Battaglia T, van Berge Henegouwen J, de Wit G, Hoes L, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4339-4351.
PMID: 39024037
Purpose: The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches....
3.
Geurts B, Zeverijn L, van Berge Henegouwen J, van der Wijngaart H, Hoes L, de Wit G, et al.
J Pathol
. 2024 May;
263(3):288-299.
PMID: 38747304
In the Drug Rediscovery Protocol (DRUP), patients with cancer are treated based on their tumor molecular profile with approved targeted and immunotherapies outside the labeled indication. Importantly, patients undergo a...
4.
Geurts B, Zeverijn L, Leek L, van Berge Henegouwen J, Hoes L, van der Wijngaart H, et al.
Clin Cancer Res
. 2024 Apr;
30(17):3735-3746.
PMID: 38630551
Purpose: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing-based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients...
5.
Spiekman I, Zeverijn L, Geurts B, Verkerk K, F Haj Mohammad S, van der Noort V, et al.
Eur J Cancer
. 2024 Mar;
202:113988.
PMID: 38471288
Background: In 2-5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 (HER2) is amplified or overexpressed. Despite prior evidence that anti-HER2 therapy confers clinical benefit (CB) in...
6.
Spiekman I, Geurts B, Zeverijn L, de Wit G, van der Noort V, Roepman P, et al.
Oncologist
. 2023 Dec;
29(5):431-440.
PMID: 38109296
Background: The prognosis of malignant primary high-grade brain tumors, predominantly glioblastomas, is poor despite intensive multimodality treatment options. In more than 50% of patients with glioblastomas, potentially targetable mutations are...
7.
Samsom K, Bosch L, Schipper L, Schout D, Roepman P, Boelens M, et al.
Nat Protoc
. 2023 Dec;
19(3):700-726.
PMID: 38092944
Two decades after the genomics revolution, oncology is rapidly transforming into a genome-driven discipline, yet routine cancer diagnostics is still mainly microscopy based, except for tumor type-specific predictive molecular tests....
8.
Koster R, Schipper L, Giesbertz N, van Beek D, Mendeville M, Samsom K, et al.
Genet Med
. 2023 Nov;
26(2):101032.
PMID: 38006283
Purpose: Genome sequencing (GS) enables comprehensive molecular analysis of tumors and identification of hereditary cancer predisposition. According to guidelines, directly determining pathogenic germline variants (PGVs) requires pretest genetic counseling, which...
9.
van der Hoeven J, Monkhorst K, van de Wouw A, Roepman P
Ned Tijdschr Geneeskd
. 2023 Oct;
167.
PMID: 37823879
Cancer of unknown primary origin (CUP) remains a serious problem. The incidence in the Netherlands is stable, 1-2 percent of all new cancer cases. In general, patients undergo a long...
10.
Zeverijn L, Looze E, Thavaneswaran S, van Berge Henegouwen J, Simes R, Hoes L, et al.
Int J Cancer
. 2023 Jul;
153(7):1413-1422.
PMID: 37424386
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical...